



# **T-Series Call for Proposals T01 and T02**

Information Deck

# Overview and Vision of NATi



*(Pronounced "Net-eye")*

To build Singapore into a regional hub for nucleic acid therapeutics research, clinical translation, and commercialisation.

NATi harnesses the potential of nucleic acids to **treat diseases using RNA molecules**. This initiative bolsters strategic partnerships and propels healthcare innovations, benefiting Singapore.

## Outlook of Singapore's NAT Activities

2023-2025



### **Building Capabilities**

Expand pipeline & establish capabilities

2026-2030



### **Grow Local Biotech Ecosystem**

Encourage local biotech growth, attract labs, expand talent, support national vaccine initiatives

Beyond 2030



### **Anchor and Strengthen NAT Industry**

Catalyse drug development, maintain capacity to enable nucleic acid therapeutics and vaccines

# Applicant Eligibility

1. The Lead Investigator and Co-Investigators as defined in Grant Terms and Conditions should:
  - a. Hold a primary appointment in a Singapore publicly funded research institution or an institute of higher learning (IHL). The Lead Investigator must hold a primary appointment of at least 0.7 FTE in Singapore.
  - b. Lead a laboratory or research programme which carries out research in Singapore
  - c. Possess track record of leadership ability in coordinating research programmes and providing mentorship to research teams as well as having productive research outcomes. A track record in securing IRS will be advantageous.
2. Exceptions to the above eligibility criteria will be considered on a case-by-case basis. Please submit a request to the NATi Coordinating Office.
3. Collaborators as defined in Grant Terms and Conditions are not eligible to receive NATi funding. Companies can participate in NATi projects only as collaborators. There are no exceptions.

# **T01**

## **Outbreak Response**

# T01 Grant Details

Please refer to the Frequently Asked Questions (FAQs) for more information.

## **Funding Quantum and Duration**

Up to S\$300K (incl. 30% indirect costs), max. 12 months

## **Eligibility**

Singapore Public Sector Researchers as defined in previous slide

## **Grant Period**

Applications are accepted anytime until **30 Sep 2025, 12pm, Singapore Time**

## **Grant Scope**

Rapid preclinical development of an RNA vaccine or therapeutic in response to an ongoing disease outbreak

## **Key Requirements**

- The outbreak should present a significant public health risk to Singapore
- The path to clinic should be identified upfront to facilitate a rapid response

## **How to apply**

Email completed application form and supporting documents to [enquiry@nati.sg](mailto:enquiry@nati.sg)

# Objectives of NATi T01 Call for Proposals

The NATi T01 Rolling Call for Proposals aims to develop an **RNA vaccine or therapeutic** in **rapid response to an outbreak** that presents a significant public health risk to Singapore.



Projects are expected to advance rapidly through **collaboration with one or more NATi-funded platform** and **identify a clear path to the clinic.**



# Evaluation Criteria

- 1** Significance of Outbreak to Singapore
- 2** Relevance to NATi
- 3** Scientific quality and competitiveness
- 4** Effectiveness of project management
- 5** Appropriateness of the requested budget

# T01 Application and Evaluation Process

## Proposal Submission

- Lead Investigator submits full proposal and supporting documents to [enquiry@nati.sg](mailto:enquiry@nati.sg) by deadline

## Review

- Evaluation will begin upon acknowledgement of receipt
- Lead Investigator may be invited to present to a review panel

## Award

- Outcome of review will be communicated to the Lead Investigator within 2 – 3 months of full proposal submission
- After final budget review, successful applicants will be issued In-Principle Approval and subsequently a Letter of Award.



# **T02**

## **Research Collaboration with Industry**

# T02 Grant Details

Please refer to the Frequently Asked Questions (FAQs) for more information.

## **Funding Quantum and Duration**

Up to S\$5M (incl. 30% indirect costs), max. 36 months

## **Eligibility**

Singapore Public Sector Researchers as defined in previous slide

## **Grant Period**

Applications are accepted anytime until **30 Sep 2025, 12pm, Singapore Time**

## **Grant Scope**

Strategic research projects with industry that can help to accelerate the development and commercialisation of RNA drugs and RNA therapeutics-related technologies in Singapore

## **Key Requirements**

- A Research Collaboration Agreement (RCA) with an industry partner should be in its final stages of negotiation and/or execution, pending NATi's funding
- Cash contributions from industry partner is required, and should match at least 50% of the total grant request. In-kind contributions will be taken into consideration during evaluation.

## **How to apply**

Email completed Letter of Intent (LOI) and supporting documents to [enquiry@nati.sg](mailto:enquiry@nati.sg)

# Objectives of NATi T02 Call for Proposals

The NATi T02 Call for Proposals aims **to foster industry collaborations** and **generate economic outcomes** for Singapore in the nucleic acid therapeutics sector.



Applicants are expected to **collaborate on strategic research projects** with an industry partner **to accelerate the development and commercialisation of RNA drugs and RNA therapeutics-related technologies** in Singapore.



# Evaluation Criteria

1	Relevance to NATi
2	Potential for commercial adoption
3	Scientific quality and innovativeness
4	Experience and expertise of the team
5	Effectiveness of project management
6	Appropriateness of the requested budget
7	Strength of intellectual property (IP) strategy
8	International competitiveness

# Contribution Details – Example 1

***This example assumes a 50:50 contribution from public- and private-sector parties.*** It is not eligible for T02 funding as the cash contributions are zero.

Cash contributions cannot be zero.

	Host Institution	Partner Institution (where applicable, add as required)	Industry Collaborator
Cash Contributions (S\$) according to RCA	N.A.	N.A.	0
In-Kind Contributions (S\$) according to RCA	800,000	200,000	1,000,000
<b>TOTAL CONTRIBUTIONS (S\$):</b>	<b>800,000</b> <i>(including Investigator's EOM)</i>	<b>200,000</b> <i>(including Investigator's EOM)</i>	<b>1,000,000</b>
Percentage Total Contribution	50%		50%
Requested T02 funding (incl. 30% indirect costs) (S\$)	<b>500,000</b> <i>(Investigator's EOM is non-fundable)</i>	<b>150,000</b> <i>(Investigator's EOM is non-fundable)</i>	Cash contribution from NATi: S\$650K Cash contribution from industry: S\$0

## Current state of RCA:

- ☐ The scope is under discussion.
- ☐ The scope has been finalised.
- ☐ The budget has been finalised based on agreed scope.
- ☐ The legal terms including Intellectual Property (IP) clauses have been finalised.
- ☒ The RCA has been signed (RCAs **should not** be signed before submission. Please refer to FAQ for more information).
- ☐ Others (please specify):

**RCA should not be signed before application to NATi for T02 funding**

# Contribution Details – Example 2

***This example assumes that there is 50:50 contribution from public- and private-sector parties.*** This is eligible to be considered for T02 funding because the cash contributions match at least 50% of the total grant request.

	Host Institution	Partner Institution (where applicable, add as required)	Industry Collaborator
Cash Contributions (S\$) according to RCA	N.A.	N.A.	400,000
In-Kind Contributions (S\$) according to RCA	800,000	200,000	600,000
<b>TOTAL CONTRIBUTIONS (S\$):</b>	<b>800,000</b> <i>(including Investigator's EOM)</i>	<b>200,000</b> <i>(including Investigator's EOM)</i>	<b>1,000,000</b>
Percentage Total Contribution	50%		50%
<b>Requested T02 funding (incl. 30% indirect costs) (S\$)</b>	<b>500,000</b> <i>(Investigator's EOM is non-fundable)</i>	<b>150,000</b> <i>(Investigator's EOM is non-fundable)</i>	Cash contribution from NATi: S\$650K Cash contribution from industry: S\$400K

## Current state of RCA:

- ☐ The scope is under discussion.
- ☒ The scope has been finalised.
- ☐ The budget has been finalised based on agreed scope.
- ☐ The legal terms including Intellectual Property (IP) clauses have been finalised.
- ☐ The RCA has been signed (RCAs **should not** be signed before submission. Please refer to FAQ for more information).
- ☐ Others (please specify):

# Contribution Details – Example 3

***This example assumes that there is 60:40 contribution from public- and private-sector parties.*** This is eligible to be considered for T02 funding as the cash contributions are 50% of total grant request.

	Host Institution	Partner Institution (where applicable, add as required)	Industry Collaborator
Cash Contributions (S\$) according to RCA	N.A.	N.A.	750,000
In-Kind Contributions (S\$) according to RCA	800,000	1,000,000	450,000
<b>TOTAL CONTRIBUTIONS (S\$):</b>	<b>800,000</b> <i>(including Investigator's EOM)</i>	<b>1,000,000</b> <i>(including Investigator's EOM)</i>	<b>1,200,000</b>
Percentage Total Contribution	60%		40%
Requested T02 funding (incl. 30% indirect costs) (S\$)	<b>700,000</b> <i>(Investigator's EOM is non-fundable)</i>	<b>800,000</b> <i>(Investigator's EOM is non-fundable)</i>	Cash contribution from NATi: S\$1.5M Cash contribution from industry: S\$750K

## Current state of RCA:

- ☐ The scope is under discussion.
- ☐ The scope has been finalised.
- ☒ The budget has been finalised based on agreed scope.
- ☐ The legal terms including Intellectual Property (IP) clauses have been finalised.
- ☐ The RCA has been signed (RCAs **should not** be signed before submission. Please refer to FAQ for more information).
- ☐ Others (please specify):

# T02 Application and Evaluation Process



- Lead Investigator submits LOI and supporting documents to [enquiry@nati.sg](mailto:enquiry@nati.sg) by deadline
- Evaluation will begin upon acknowledgement of receipt and results of the LOI will be communicated to the Lead Investigator within 2 – 3 weeks of LOI submission.
- Shortlisted applicants will be invited to submit a full written proposal
- Lead Investigator may be invited to present
- Outcome of review will be communicated to the Lead Investigator within 2 – 3 months of full proposal submission
- After final budget review, successful applicants will be issued In-Principle Approval and subsequently a Letter of Award.



# Contact Us

**For general enquiries, please contact:**

[enquiry@nati.sg](mailto:enquiry@nati.sg)